The Motley Fool
24 Dec 2025, 23:00 UTC · 47w ago
Why Edgewise Therapeutics Stock Rocked the Market Today
Impact · against what's priced in
Edgewise Therapeutics saw a significant price surge following positive interim Phase 2 data for EDG-7500 and faster-than-expected enrollment in its CIRRUS-HCM trial. The combination of demonstrated clinical activity and a favorable safety profile materially derisks the asset's path toward Phase 3.
- EWTX+0.70
No priced-in read yet
- In context
Interim Phase 2 data showing clinical activity across HCM disease markers and a favorable safety profile provide concrete evidence of efficacy that reduces binary trial risk. Additionally, exceeding year-end enrollment goals for Part D of the CIRRUS-HCM trial suggests strong physician interest and potential acceleration of the development timeline.





